AFREZZA® (insulin human) Inhalation Powder

First Page		Document Content
Chronic lower respiratory diseases Pulmonary function testing Occupational diseases Chronic obstructive pulmonary disease Inhalable insulin Spirometry Asthma Diabetes management MannKind Corporation Pulmonology Respiratory therapy Medicine		AFREZZA® (insulin human) Inhalation Powder Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 349,07 KB Share Document on Facebook

	PRESS RELEASE Sanofi and MannKind Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin Paris and Valencia, Calif. - August 11, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) and Ma DocID: GZbg - View Document
	XX-1 CI-1 AFREZZA® Technosphere® Insulin Inhalation System NDA[removed] DocID: BdT0 - View Document
	FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting The Marriott Inn and Conference Center, University of Maryland Unive DocID: kbC4 - View Document
	FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting The Marriott Inn and Conference Center, University of Maryland Unive DocID: k1ok - View Document
	AFREZZA® (insulin human) Inhalation Powder DocID: eTYy - View Document